We are live on ! Find out more
LIMNW

Liminatus Pharma Warrants
LIMNW

21 hedge funds and large institutions have $72.6K invested in Liminatus Pharma Warrants in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

11.29% less ownership

Funds ownership: 31.82% → 20.53% (-11%)

13% less funds holding

Funds holding: 24 → 21 (-3)

24% less capital invested

Capital invested by funds: $95K → $72.6K (-$22.4K)

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
21
Holders Change
-3
Holders Change %
-12.5%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
3
Closed
3
Calls
$3K
Puts
–
Net Calls
+$3K
Net Calls Change
+$1K

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$19

Top Sellers

Rank Fund Capital Flow
1
CS
Clear Street
New York
-$51.5K
2
WAM
Wolverine Asset Management
Illinois
-$1.5K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$837
4
GS
GTS Securities
Florida
-$555
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$434

LIMNW Hedge Fund Activity: Q1 2026 in Review

21 of the 8,205 institutional investors tracked by Wall St. Rank reported a position in Liminatus Pharma Warrants (LIMNW) for Q1 2026, worth a combined $72.6K — down 24% from $95K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of LIMNW and 0 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 1 added.

The largest buyer was UBS Group, adding an estimated $19. The largest seller was Clear Street, cutting an estimated $51.5K.

  • 21 institutional investors held Liminatus Pharma Warrants (LIMNW) as of Q1 2026, down from 24 in Q4 2025.
  • Funds reported $72.6K of Liminatus Pharma Warrants stock for Q1 2026, down 24% quarter-over-quarter.
  • 0 funds opened new Liminatus Pharma Warrants positions in Q1 2026 and 3 closed out, a net change of -3 holders.
  • The largest Liminatus Pharma Warrants buyer in Q1 2026 was UBS Group, an estimated $19 added.
  • The largest Liminatus Pharma Warrants seller in Q1 2026 was Clear Street, an estimated $51.5K sold.

Based on aggregated 13F filings for Q1 2026.